PT  - JOURNAL ARTICLE
AU  - Liu, Ji
AU  - Zhou, Guanen
AU  - Kolls, Bradley J
AU  - Tan, Yanli
AU  - Fang, Chuan
AU  - Wang, Haichen
AU  - Laskowitz, Daniel T
TI  - Apolipoprotein E mimetic peptide CN-105 improves outcome in a murine model of SAH
AID  - 10.1136/svn-2018-000152
DP  - 2018 Dec 01
TA  - Stroke and Vascular Neurology
PG  - 222--230
VI  - 3
IP  - 4
4099  - http://svn.bmj.com/content/3/4/222.short
4100  - http://svn.bmj.com/content/3/4/222.full
AB  - Objective Subarachnoid haemorrhage (SAH) accounts for 3% of all strokes, and is associated with significant morbidity and mortality. There is growing evidence implicating apolipoprotein E (apoE) in mediating adaptive anti-inflammatory and neuroprotective responses following ischaemic and traumatic brain injury. In the current study, we test the efficacy of a small apoE mimetic peptide, CN-105 in a murine model of SAH.Methods Mice subjected to SAH received repeated intravenous injections of CN-105 every 12 hours for 3 days, with the first dose given 2 hours after injury. Daily functional outcomes were assessed by rotarod and neurological severity score. Haemorrhage grade and cerebral vascular diameters were measured at 5 days post-SAH. Cerebral microgliosis, neuronal degeneration and survival were analysed at 5 and 35 days post-SAH, respectively.Results CN-105 reduces histological evidence of inflammation, reduces vasospasm and neuronal injury and is associated with improved long-term behavioural outcomes in a murine model of SAH.Conclusions Given its favourable pharmacokinetic profile, central nervous system penetration and demonstration of clinical safety, CN-105 represents an attractive therapeutic candidate for treatment of brain injury associated with SAH.